Transgenic expression of miR-133a improved myocardial fibrosis and diastolic function post-transverse aortic constriction without affecting hypertrophy, though it increased QT intervals.
Does transgenic expression of miR-133a improve cardiac remodeling and function in pressure-overloaded adult hearts?
In adult mouse models, maintaining miR-133a levels during pressure overload improves myocardial fibrosis and diastolic function but does not prevent hypertrophy and alters electrical repolarization.
RATIONALE: MicroRNA (miR)-133a regulates cardiac and skeletal muscle differentiation and plays an important role in cardiac development. Because miR-133a levels decrease during reactive cardiac hypertrophy, some have considered that restoring miR-133a levels could suppress hypertrophic remodeling. OBJECTIVE: To prevent the "normal" downregulation of miR-133a induced by an acute hypertrophic stimulus in the adult heart. METHODS AND RESULTS: miR-133a is downregulated in transverse aortic constriction (TAC) and isoproterenol-induced hypertrophy, but not in 2 genetic hypertrophy models. Using MYH6 promoter-directed expression of a miR-133a genomic precursor, increased cardiomyocyte miR-133a had no effect on postnatal cardiac development assessed by measures of structure, function, and mRNA profile. However, increased miR-133a levels increased QT intervals in surface electrocardiographic recordings and action potential durations in isolated ventricular myocytes, with a decrease in the fast component of the transient outward K+ current, I(to,f), at baseline. Transgenic expression of miR-133a prevented TAC-associated miR-133a downregulation and improved myocardial fibrosis and diastolic function without affecting the extent of hypertrophy. I(to,f) downregulation normally observed post-TAC was prevented in miR-133a transgenic mice, although action potential duration and QT intervals did not reflect this benefit. miR-133a transgenic hearts had no significant alterations of basal or post-TAC mRNA expression profiles, although decreased mRNA and protein levels were observed for the I(to,f) auxiliary KChIP2 subunit, which is not a predicted target. CONCLUSIONS: These results reveal striking differences between in vitro and in vivo phenotypes of miR expression, and further suggest that mRNA signatures do not reliably predict either direct miR targets or major miR effects.
Matkovich et al. (Fri,) conducted a other in Cardiac hypertrophy and myocardial fibrosis. Transgenic expression of miR-133a vs. Non-transgenic controls was evaluated on Myocardial fibrosis, diastolic function, and hypertrophy. Transgenic expression of miR-133a improved myocardial fibrosis and diastolic function post-transverse aortic constriction without affecting hypertrophy, though it increased QT intervals.